Letter from AAM: Mr. President, Block the BLOCKING Act! | Association for Accessible Medicines
AAM All Access Podcast - Dan Leonard speaks to David Gaugh (AAM), Jessica Daley (Premier Inc) and Steven Schondelmeyer (University of Minnesota).

Letter from AAM: Mr. President, Block the BLOCKING Act!

The Lower Health Care Costs Act, under consideration in both the House and Senate, includes a provision (Section 407 — the BLOCKING Act) that would significantly harm the competition that lowers prescription drug prices for America’s patients and taxpayers. AAM CEO Chester “Chip” Davis, Jr. wrote to President Trump to urge him to oppose the BLOCKING Act.

The BLOCKING Act would undermine the only incentive generic drug developers have to file their applications with the FDA as early as possible — to bring savings to patients and taxpayers as quickly as possible. This proposal would result in delayed price competition from FDA-approved generic medicines and longer monopolies for expensive brand-name drugs.

Mr. President: Please block the BLOCKING Act so Congress does not destroy your pro-competitive policies that have produced such savings over the last three years.

Read Letter

Take Action

Learn More


Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.